Overexpression of HIPK2 circumvents the blockade of apoptosis in chemoresistant ovarian cancer cells

Gynecologic Oncology

Volumn 109, Issue 3, 2008, Pages 403-410

  Puca, Rosa ^a   Nardinocchi, Lavinia ^a   Pistritto, Giuseppa ^b   D'Orazi, Gabriella ^a,c  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c UNIVERSITY OF CHIETI   (Italy)

Author keywords

Apoptosis; Caspase activity; Chemotherapeutic drugs; HIPK2; Ovarian cancer; p53

Indexed keywords

CASPASE 3; CASPASE 8; CASPASE 9; CISPLATIN; DOXORUBICIN; HOMEODOMAIN INTERACTING PROTEIN KINASE 2; LUCIFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN P53;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CONTROLLED STUDY; CYSTADENOCARCINOMA; ENZYME ACTIVITY; ENZYME DEGRADATION; FEMALE; GENE INDUCTION; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; OVARY CARCINOMA; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; WESTERN BLOTTING;

APOPTOSIS; CARRIER PROTEINS; CASPASES; CELL LINE, TUMOR; CISPLATIN; CYSTADENOCARCINOMA, SEROUS; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OVARIAN NEOPLASMS; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEIN P53;

EID: 44549085662     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.02.018     Document Type: Article

References (31)

1. Borst P., Jonkers J., and Rottenberg S. What makes tumors multidrug resistant?. Cell Cycle 6 (2007) 2782-2787
2. Fraser M., Leung B.M., Yan X., Dan H.C., Cheng J.Q., and Tsang B.K. p53 is a determinant of X-linked inhibitor of apoptosis protein/Akt-mediated chemoresistance in human ovarian cancer cells. Cancer Res 63 (2003) 7081-7088
3. Siddik Z.H. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22 (2003) 7265-7279
4. Haupt S., Berger M., Goldberg Z., and Haupt Y. Apoptosis-the p53 network. J Cell Sci 116 (2003) 4077-4085
5. Xu Y. Regulation of p53 responses by post-translational modifications. Cell Death Differ 10 (2003) 400-403
6. Brooks C.L., and Gu W. Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. Curr Opin Cell Biol 2 (2003) 164-171
7. Giaccia A.J., and Kastan M.B. The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev 12 (1998) 2973-2983
8. Kim Y.H., Choi C.Y., Lee S., Conti M.A., and Kim Y. Homeodomain-interacting protein kinases, a novel family of co-repressors for homeodomain transcription factors. J Biol Chem 273 (1998) 875-879
9. D'Orazi G., Cecchinelli B., Bruno T., Manni I., Higashimoto Y., Saito S., et al. Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser46 and mediates apoptosis. Nat. Cell Biol 4 (2002) 11-19
10. Hofmann T.G., Moller A., Sirma H., Zentgraf H., Taya Y., Droge W., et al. Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2. Nat. Cell Biol 4 (2002) 1-10
11. Di Stefano V., Rinaldo C., Sacchi A., Soddu S., and D'Orazi G. Homeodomain-interacting protein kinase-2 activity and p53 phosphorylation are critical events for cisplatin-mediated apoptosis. Exp Cell Res 293 (2004) 311-320
12. Wesierska-Gadek J., Schmitz M.L., and Ranftler C. Roscovitine-activated HIP2 kinase induces phosphorylation of wtp53 at Ser-46 in human MCF-7 breast cancer cells. J Cell Biochem 100 (2007) 865-874
13. Dauth I., Kruger J., and Hofmann T.G. Homeodomain-interacting protein kinase 2 is the ionizing radiation-activated p53 serine 46 kinase and is regulated by ATM. Cancer Res 67 (2007) 2274-2279
14. Choi D.W., Seo Y.-M., Kim E.-A., Sung K.S., Ahn J.W., Park S.-J., et al. Ubiquitination and degradation of homeodomain-interacting protein kinase 2 (HIPK2) by WD40-repeat/SOCS box protein WSB-1. J Biol Chem (2007) 10.1074/jbc.M708873200
15. Pistritto G., Puca R., Nardinocchi L., Sacchi A., and D'Orazi G. HIPK2-induced p53Ser46 phosphorylation activates the KILLER/DR5-mediated caspase-8-extrinsic apoptotic pathway. Cell Death Differ (2007) 10.1038/sj.cdd.4402186
16. Gresko E., Roscic A., Vichalkovski S., del Sal G., and Schmitz M.L. Autoregulatory control of the p53 response by caspases-mediated processing of HIPK2. EMBO J 25 (2006) 1883-1894
17. Harris S.L., and Levine A.J. The p53 pathway: positive and negative feedback loops. Oncogene 24 (2005) 2899-2908
18. Andrews P.A., Velury S., Mann S.C., and Howell S.B. cis-Diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Res 48 (1998) 68-73
19. Delmastro D.A., Li J., Vaisman A., Solle M., and Chaney S.G. DNA damage inducible-gene expression following platinum treatment in human ovarian carcinoma cell lines. Cancer Chemother Pharmacol 39 (1997) 245-253
20. Oda K., Arakawa H., Tanaka T., Matsuda K., Tanikawa C., Mori T., et al. P53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 102 (2000) 849-862
21. Chen C., and Okayama H. High-efficiency transformation of mammalian cells by plasmid DNA. Mol Cell Biol 7 (1987) 2754-2756
22. Yan X., Fraser M., Qiu Q., and Tsang B.K. Over-expression of PTEN sensitizes human ovarian cancer cells to cisplatin-induced apoptosis in a p53-dependent manner. Gynecol Oncol 102 (2006) 348-355
23. Pierantoni G.M., Rinaldo C., Mottolese M., Di Benedetto A., Esposito F., Soddu S., and Fusco A. High-mobility group A1 inhibits p53 by cytoplasmic relocalization of its proapoptotic activator HIPK2. J Clin Invest 117 (2007) 693-702
24. Hollstein M., Sidransky D., Vogelstein B., and Harris C.C. P53 mutations in human cancers. Science 253 (1991) 49-53
25. Greenblatt M.S., Bennet W.P., Hollstein M., and Harris C.C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54 (1994) 4855-4878
26. Hollstein M., Hergenhahn M., Yang Q., Bartsch H., Wang Z.Q., and Hainaut P. New approaches to understanding p53 gene tumor mutation spectra. Mutat Res 432 (1999) 199-209
27. Vousden K.H., and Prives C. P53 and prognosis: new insights and further complexity. Cell 120 (2005) 7-10
28. Mayo L.D., Rok Seo Y., Jackson M.W., Smith M.L., Rivera Guzman J.R., Koegaonkar C.K., et al. Phosphorylation of human p53 at serine 46 determines promoter selection and whether apoptosis is attenuated or amplified. J Biol Chem 280 (2005) 25953-25959
29. Ichwan S.J.A., Yamada S., Sumreijkanchanakij P., Ibrahim-Auerkari E., Eto K., and Ikeda M.A. Defect in serine 46 phosphorylation of p53 contributes to acquisition of p53 resistance in oral squamous cell carcinoma cells. Oncogene 25 (2006) 1216-1224
30. Yoshida K., Monden M., Nakamura Y., and Arakawa H. Adenovirus-mediated p53AIP1 gene transfer as a new strategy for treatment of p53-resistant tumors. Cancer Sci 95 (2004) 91-97
31. Nakamura Y., Futamura M., Kamino H., Yoshida K., Nakamura Y., and Arakawa H. Identification of p53-46F as a super p53 with an enhanced ability to induce p53-dependent apoptosis. Cancer Sci 97 (2006) 633-641